Geoffrey Shouse

38PUBLICATIONS
176CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyHaematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Jul 30, 2026
Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.

|Jul 04, 2026
CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

|Jun 09, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

|May 18, 2026
Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.

|Feb 26, 2026
Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.

John Sharp, Paolo Strati, Subodh Bhatta

|Dec 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin

Pageof 7

Frequent Collaborators

12 joint publications

Narendranath Epperla

9 joint publications

Reem Karmali

8 joint publications

Thomas Ollila

8 joint publications

Alex F Herrera